BioLuminate Breast Cancer Detector R&D Delayed By Financing Drought
This article was originally published in The Gray Sheet
Executive Summary
BioLuminate will launch a 12-center, 1,000-patient Phase III pivotal trial to support a PMA application for its Smart Probe breast cancer detection tool as an adjunct to mammography, following completion of a 150-patient Phase I/II study later this year
You may also be interested in...
FDA Review Criteria Are Insufficient To Prompt CMS Coverage – Feigal, Tunis
Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11
FDA/CMS Device Trade Secret Memo Added To Regulatory Reform Wish List
FDA and CMS should issue a memorandum of understanding on maintaining confidentiality and trade secrets during collaborations between the agencies in evaluating new devices, according to the HHS Secretary's Advisory Committee on Regulatory Reform
BioLuminate's Smart Probe Breast Cancer Detection Trials Start In Early 2001
San Jose-based BioLuminate expects to be profitable in 2003, immediately following the commercial release of its Smart Probe breast cancer detection diagnostic tool. The privately held start-up began operations in April 2000.